

Daratumumab for Patients With Light Chain Amyloidosis

NCT06376214

Status	RECRUITING
Phase	Not Applicable
Sponsor	Nanjing University School of Medicine
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (7)

- Participants must be aged ≥18 and ≤75 years;
- Newly diagnosed AL amyloidosis ((confirmed by pathological examination with at least one major organ involvement (heart, kidney, or liver));
- In group A and B, according to the Mayo 2004 staging system, the disease is classified as stage I-IIA; In group C, according to the Mayo 2004 staging system, the disease is classified as stage IIIB: NT-proBNP >8500ng/L and cTnT >0.035μg/L or cTnI >0.01g/L;
- Participants must personally sign an informed consent form approved by the Ethics Committee before the start of the study;
- Expected survival ≥12 weeks;
- ... and 2 more (see full listing online)

Exclusion (6)

- eGFR < 30ml/min/1.73m²;
- Combined multiple myeloma;
- Acute or chronic infection requiring treatment within 30 days prior to baseline;
- Pregnant or breastfeeding women.
- Participants known to have life-threatening allergic reactions, hypersensitivity, or intolerance to Monoclonal antibodies or immune modulators.
- ... and 1 more (see full listing online)

Locations (1 total)

National Clinical Research Center for Kidney Diseases, Jinling Hospital, Nanjing, Jiangsu, China

<https://clinicaltrials.gov/study/NCT06376214>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).